Psoriatic Arthritis

Prescription drugs costs for patients with psoriatic arthritis tended to be higher than comparable costs for ankylosing spondylitis.

Balanced approach needed to better discriminate between high and low disease activity.

Patients who received golimumab and methotrexate reported larger improvements than monotherapy patients.

Novel oral treatment for moderate-to-severe plaque psoriasis deemed an effective option.

Significant weight loss found to reduce disease burden in psoriatic arthritis patients.

Ixekizumab found to improve skin clearance of plaque psoriasis and reduced disability when performing certain physical functions.

Cosentyx found to maintain improvements in joint and skin disease, physical function, and quality of life in PsA patients.

Combination of risk factors and PsA disease activity found increase dangers of cardiovascular disease.

Study suggests superior efficacy from older PsA drugs.

Secukinumab shows promise in the treatment of patients with psoriatic arthritis.

Improvements in itching scores maintained from week 16 to week 52 in patients who received Otezla.

Health information sharing web site helps connect patients among more than 2500 conditions.

Chronic inflammatory skin condition associated with decreased quality of life and increased all-cause mortality.

Lengthening time between treatment with anti-TNF agents may improve adherence.

Mild psoriasis, severe psoriasis, and psoriatic arthritis may also bring increased comorbidities.

Caregivers need to help patients with psoriasis understand the importance of lifestyle behavior choices.

The role of vitamin D in diseases such as psoriatic arthritis, systemic lupus erythematosus, and rheumatoid arthritis.

Psoriasis treatment may improve more than just skin issues.

A 10-second assessment may be as effective as more complex tests.

Elevated risk found for heart arrhythmia, specifically atrial fibrillation.

Lithium chloride found to slow degradation.

Patients who received secukinumab sustained improvements over one year of treatment.

Drug decreases enthesitis and dactylitis by blocking the production of cytokines that promote inflammation.

Productivity and absenteeism improved in patients with chronic inflammatory arthritides.